[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CellSight Technologies, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":129},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,39,66,87,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100639350","phase-2-18ff-arag-pet-imaging-in-alzheimers-disease-100639350",false,"NCT07611357","[18F]F-AraG PET Imaging in Alzheimer's Disease","Total-Body [18F]F-AraG PET\u002FCT Imaging to Quantify CNS and Systemic T Cell Involvement in Alzheimer's Disease","Inclusion Criteria:\n\n1. Age ≥ 55 years\n2. Prior volumetric brain MRI available. If the prior MRI scan is not acquired within 6 months of \\[18F\\]F-AraG imaging or if the investigator determines that prior MRI scan cannot be used, a new MRI scan will be acquired.\n3. Able to tolerate a PET scan, and willingness and ability to comply with all protocol required procedures.\n4. For participants of reproductive potential - defined as individuals who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or who have not undergone surgical sterilization, specifically hysterectomy and\u002For bilateral oophorectomy or bilateral salpingectomy - willingness to use effective double barrier contraceptive methods (excluding withdrawal or timing methods) up to 1 day after the administration of \\[18F\\]F-AraG\n5. Subjects with possible or probable AD based on the NIA-Alzheimer's Association working group's diagnostic guidelines for AD.\n6. Have a study partner who has significant interaction with the subject and can report on the subject's activities of daily living.\n\nExclusion Criteria:\n\n1. Clinically significant psychiatric disease other than depression.\n2. Structural brain abnormalities on MRI (e.g. large infarct or mass) likely to interfere with interpretation of a PET scan.\n3. History of significant alcohol or substance abuse\u002Fdependence within the past 5 years.\n4. Non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the PET imaging session.\n5. Current or recent investigational drug use, defined as receiving any investigational medications or participation in another investigational drug trial within the last 30 days.\n6. Serious comorbidities (malignant and nonmalignant disease or other conditions) that in the opinion of the investigator could compromise study objectives.\n7. Conditions affecting immune function or conditions caused by immune system malfunction that could interfere with imaging, including known inflammatory or immune disorders, systemic malignancy, or chronic viral infections.\n8. Pregnant or nursing individuals. All participants of reproductive potential will undergo a urine or HCG serum pregnancy test with a sensitivity of at least 25 mIU\u002FmL at screening and on the day of PET\u002FCT imaging.\n9. Prior allogeneic stem cell or solid organ transplant.\n10. Previously diagnosed myelodysplasia syndrome or history of lymphoproliferative disease prior to study entry.\n11. Active systemic autoimmune diseases.\n12. Self-reported history of dysphoria or anxiety in closed spaces (i.e., uncontrolled claustrophobia).\n13. Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n14. Body weight is more than 240 kg (529 pounds)\n15. Recent use of medications containing guanosine or cysteine analogs.\n16. Any other criteria which would make the participant unsuitable for study participation, as determined by the Principal Investigator.","ALL","55 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study evaluates the use of \\[18F\\]F-AraG PET\u002FCT imaging to quantify activated T cell involvement in patients with Alzheimer's disease (AD). Participants will undergo total-body dynamic PET imaging to assess tracer uptake in the brain and peripheral organs. Results will be compared between participants with AD and healthy controls to characterize both central nervous system and systemic immune alterations in AD",[26],"Alzheimer Disease (AD)","NOT_YET_RECRUITING","2026-05-20",{"date":30,"type":31},"2026-05-28","ACTUAL",{"date":33,"type":20},"2026-05-16",{"date":35,"type":20},"2029-12-16",{"name":37,"class":38},"CellSight Technologies, Inc.","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":49,"conditions":50,"keywords":53,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100425068","phase-2-imaging-immune-activation-in-covid-19-100425068","NCT04815096","Imaging Immune Activation in COVID-19","Inclusion Criteria:\n\n* Age \\>18 years\n* Ability to read and understand written informed consent document\n* Have a recent diagnosis of SARS-CoV-2 infection as defined by a prior positive SARS-CoV-2 nucleic acid-based diagnostic test performed in a clinical laboratory on one or more nasopharyngeal or respiratory secretion samples.\n* \\> 14 days since onset of COVID-19 symptoms (or if no symptoms, from time of initial nucleic acid based diagnostic test).\n* Laboratory evaluations obtained within 60 days prior to entry.\n\n  * Platelet count ≥75,000\u002Fmm3\n  * ANC \\>1000\u002Fmm3\n  * Aspartate aminotransferase (AST) \\\u003C3 x ULN\n  * Alanine aminotransferase (ALT) \\\u003C3 x ULN\n  * Calculated creatinine clearance (CrCl) ≥60 mL\u002Fmin as estimated by the Cockcroft-\n  * Gault equation\n\nExclusion Criteria:\n\n* Any medical condition that would compromise the imaging acquisition, in the opinion of the investigator\n* Participants who are pregnant (female participants of childbearing age will be tested prior to injection of imaging agent at entry visit\u002Finitial visit - positive test will exclude from further participation in the study)\n* Participants who are breastfeeding\n* Female participants of reproductive potential (defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or women who have not undergone surgical sterilization, specifically hysterectomy and\u002For bilateral oophorectomy or bilateral salpingectomy) must have a negative urine or serum pregnancy test with a sensitivity of at least 25 mIU\u002FmL performed within 24 hours prior to PET imaging. Females of reproductive potential will need to be on 2 forms of birth control (excluding withdrawal or timing methods).\n* Participants who have had prior allogeneic stem cell or solid organ transplant.\n* Screening absolute neutrophil count \\\u003C1,000 cells\u002Fmm3, platelet count \\\u003C75,000 cells\u002Fmm3, hemoglobin \\\u003C 8 mg\u002FdL, estimated creatinine clearance \\\u003C60 mL\u002Fminute, aspartate aminotransferase \\>3 x ULN, alanine aminotransferase \\>3 x ULN.\n* Known SARS-CoV-2 shedding within 5 days of PET imaging.\n* Previously diagnosed myelodysplasia syndrome or history of lymphoproliferative disease prior to study entry\n* Active systemic autoimmune diseases not related to COVID-19.\n* COVID-19 vaccine prior to the first PET imaging session. Participants may receive COVID-19 vaccination after the first PET imaging session and the optional second PET scan, with the scan being performed at least 2 weeks following the most recent vaccine dose.\n* Prior PET scan or therapeutic radiation within 1 year of study enrollment.","18 Years",{"count":47,"type":20},80,[23],"This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \\[18F\\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.",[51,52],"Covid19","SARS-CoV Infection",[54,55],"PET-CT Imaging","[18F]F-AraG","RECRUITING","2026-05-05",{"date":59,"type":31},"2026-05-08",{"date":61,"type":31},"2021-04-15",{"date":63,"type":20},"2028-10-01",{"name":37,"class":38},1,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":65},"100524334","phase-2-imaging-advanced-nsclc-patients-undergoing-pd-1pd-l1-directed-therapy-using-18f-farag-100524334","NCT06107374","Imaging Advanced NSCLC Patients Undergoing PD-1\u002FPD-L1 Directed Therapy Using [18F]-FARAG","Imaging of T-cell Activation With [18F]F-araG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1\u002FPD-L1 Directed Therapy","Inclusion Criteria:\n\n1. Histologically confirmed NSCLC and planned to undergo immunotherapy as monotherapy or as combination therapy for advanced\u002Fmetastatic disease.\n2. Measurable disease.\n3. ECOG performance status of 0, 1 or 2.\n4. Subjects are willing to be followed at the University of Iowa.\n\nExclusion Criteria:\n\n1. Serious comorbidities that in the opinion of the investigator\u002Fsponsor could compromise protocol objectives.\n2. Pregnant women or nursing mothers.\n3. Patients with severe claustrophobia.",{"count":74,"type":20},20,[23],"This pilot study uses \\[18F\\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors. The study's main objectives are to quantify the change in \\[18F\\]F AraG PET signal before and while on CkIT therapy and to correlate this change in \\[18F\\]F AraG PET signal with radiographic response.\n\nTo explore these objectives, eligible subjects will undergo pre- and on - CkIT treatment \\[18F\\]F AraG PET\u002FCT scans, and will be followed up for 12 months for assessment of radiographic and clinical outcomes. This study is a single-site, open label, non randomized, single arm pilot trial. Patients and care providers will not be blinded to any part of the study.",[78],"Advanced Non Small Cell Lung Cancer","2024-10-22",{"date":81,"type":31},"2024-10-24",{"date":83,"type":31},"2023-11-01",{"date":85,"type":20},"2026-03-31",{"name":37,"class":38},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":65},"100522606","phase-2-test-retest-evaluation-of-18ff-arag-pet-100522606","NCT06084806","Test-retest Evaluation of [18F]F-AraG PET","Test-retest Evaluation of [18F]F-AraG PET in Non-small Cell Lung Cancer (NSCLC) Patients","Inclusion Criteria:\n\n1. Patients (\\>18 years old) with a histologically confirmed NSCLC and a candidate to receive immunotherapy as monotherapy or as combination therapy for advanced\u002Fmetastatic disease.\n2. Measurable disease.\n3. ECOG performance status of 0, 1 or 2.\n\nExclusion Criteria:\n\n1. Serious comorbidities that in the opinion of the investigator\u002Fsponsor could compromise protocol objectives.\n2. Pregnant women or nursing mothers.\n3. Patients with severe claustrophobia.",{"count":19,"type":20},[23],"This pilot study aims to evaluate the test-retest variability of \\[18F\\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \\[18F\\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two \\[18F\\]F-AraG PET\u002FCT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.",[98],"Non-small Cell Lung Cancer",{"date":81,"type":31},{"date":101,"type":31},"2023-10-31",{"date":103,"type":20},"2025-10-31",{"name":37,"class":38},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":45,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":65},"100338300","phase-2-imaging-immune-activation-in-hiv-by-pet-mr-100338300","NCT03684655","Imaging Immune Activation in HIV by PET-MR","Imaging Immune Activation in HIV Infection","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Ability to read and understand written informed consent document\n3. HIV infection, and Initiated a combination ART regimen, or, has never received ART, or, has received ART in the past, but has not been taking for a least 1 week prior to study imaging.\n\n   (Of note, per Department of Health and Human Services (DHHS) guidelines, the protocol team will strongly recommend that all HIV+ participants initiate ART who not done so already, both for their own health and to prevent the transmission of HIV infection.)\n4. Laboratory evaluations obtained within 60 days prior to entry. i. Platelet count ≥100,000\u002Fmm3 ii. ANC \\>1500\u002Fmm3 iii. Aspartate aminotransferase (AST) \\\u003C2 x ULN iv. Alanine aminotransferase (ALT) \\\u003C2 x ULN v. CD4+ T cell count \\>100 cells\u002Fmm3 for HIV infected individuals vi. Calculated creatinine clearance (CrCl) ≥60 mL\u002Fmin as estimated by the Cockcroft-Gault equation: For men, (140 - age in years) x (body weight in kg) ÷ (serum creatinine in mg\u002FdL x 72) = CrCl (mL\u002Fmin)\\*\n\n   * For women, multiply the result by 0.85 = CrCl (mL\u002Fmin)\n\nExclusion Criteria:\n\n1. Exclusion criteria will include any contra-indication to MRI, including permanent pacemaker, implantable metallic device\u002F prosthetic, aneurysm clip, non-removable piercing, or severe claustrophobia\n2. Any medical condition that would compromise the imaging acquisition, in the opinion of the investigator\n3. Individuals who have received systemic immune modifying therapy within 60 days of study enrollment (excluding HIV DNA vaccine).\n4. Participants who are pregnant (female participants of childbearing age will be tested prior to injection of imaging agent at entry visit\u002Finitial visit - positive test will exclude from further participation in the study)\n5. Participants who are breastfeeding\n6. Female participants of reproductive potential (defined as women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months), or women who have not undergone surgical sterilization, specifically hysterectomy and\u002For bilateral oophorectomy or bilateral salpingectomy) must have a negative urine or serum pregnancy test with a sensitivity of at least 25 mIU\u002FmL performed at the entry\u002Finitial visit, and again within 24 hours prior to PET imaging. Females of reproductive potential will need to be on 2 forms of birth control (excluding withdrawal or timing methods).\n7. Participants who have had prior allogeneic stem cell or solid organ transplant\n8. Screening absolute neutrophil count \\\u003C1,500 cells\u002Fmm3, platelet count \\\u003C100,000 cells\u002Fmm3, hemoglobin \\\u003C 8 mg\u002FdL, estimated creatinine clearance \\\u003C60 mL\u002Fminute, aspartate aminotransferase \\>2 x ULN, alanine aminotransferase \\>2 x ULN.\n9. Serious illness requiring hospitalization or parental antibiotics within the preceding 3 months\n10. Current HIV-related opportunistic infection such as pneumocystis pneumonia, disseminated microbacterial infection, invasive cryptococcal disease, candidal esophagitis (limited oral thrush acceptable) and cerebral toxoplasmosis\n11. Previously diagnosed myelodysplasia syndrome. or history of lymphoproliferative disease prior to study entry\n12. History of congestive heart failure as defined by physician documentation in the medical record at any time prior to screening that required medication for heart failure or that required medical management within 1 year prior to study entry\n13. Active Hepatitis C virus (HCV) infection. Prior history of treated HCV infection with sustained virological response will be allowed.\n14. Active systemic autoimmune diseases.\n15. Routine clinical vaccination within 14 days of study entry",{"count":113,"type":20},30,[23],"This is a single center exploratory imaging study involving one intravenous microdose of \\[18F\\]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels \\>5,000 copies\u002FmL will be enrolled. Up to 30 participants will be enrolled with HIV.",[117],"HIV Infections",[119,120,121,122],"HIV infection","Positron Emission Tomography","F-AraG","Magnetic Resonance Imaging",{"date":81,"type":31},{"date":125,"type":31},"2018-09-21",{"date":127,"type":20},"2025-11-01",{"name":37,"class":38},""]